EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Sasaki
Hidefumi
H
Endo
Katsuhiko
K
Mizuno
Kotaro
K
Yano
Motoki
M
Fukai
Ichiro
I
Yamakawa
Yosuke
Y
Fujii
Yoshitaka
Y
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D004273:DNA, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D000077156:Gefitinib; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D015996:Survival Rate / Q000639:trends
D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib